TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023. Q4 2023 and Full Year 2023 Highlights:   Q4 2023 FY 2023 Revenues   $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share   $0.41 $(0.50) Non-GAAP diluted EPS   $1.00 $2.56 Cash flow generated from operating activities   $1,184 million $1,368 million ...